Home / Uncategorized  / Glenmark gets nod for favipiravir to treat mild to moderate COVID-19 patients

Glenmark gets nod for favipiravir to treat mild to moderate COVID-19 patients

Glenmark Pharmaceuticals has received manufacturing and marketing approval from India's drug regulator to launch the oral antiviral drug favipiravir for the treatment of mild to moderate COVID-19 patients in India, the company said in a

Glenmark Pharmaceuticals has received manufacturing and marketing approval from India’s drug regulator to launch the oral antiviral drug favipiravir for the treatment of mild to moderate COVID-19 patients in India, the company said in a statement on Friday. “It is for restricted emergency use in India,” Glenmark Pharmaceuticals added.

pandey.satish056@gmail.com

Review overview
NO COMMENTS

POST A COMMENT